tradmap

AIM AIM ImmunoTech Inc.

$0.38 -1.56%

Healthcare · Biological Products, (No Diagnostic Substances)

AIM ImmunoTech Inc. (AIM) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $6 million. Shares last traded at $0.38, 98.9% below their 52-week high. Over the past year the stock is up 200.6%. Net profit margin is -15861.4%, below the peer median of 6.3%. Revenue declined 48.2% year over year.

Market Cap
$6M
Shares Out
14.6M
EPS (TTM)
$-17.80
P/E Ratio
P/S Ratio
62.59
P/B Ratio
2.59
Dividend / Share
Dividend Yield
52-Week High
$34.53
52-Week Low
$0.06
Volume
52,516
Avg Vol (3m)
448,994.175

Performance

1W
-15.56%
1M
-1.77%
3M
-58.80%
6M
-72.19%
YTD
-68.48%
1Y
+200.64%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
44.90
SMA (50)
$0.45
SMA (200)
$1.29
Price vs SMA50
-16.74%
Price vs SMA200
-70.68%
ATR (14)
$0.13

Financials

Revenue
$0M
Net Income
$-14M
Gross Margin
Operating Margin
-13254.5%
Net Margin
-15861.4%
Return on Equity
-656.8%
Return on Assets
-162.6%
Current Ratio
1.01
Debt / Equity
1.98
Revenue Growth (YoY)
-48.2%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.69 2026-05-15
FY 2025 $-8.62 2026-03-27
Q3 2025 $-8.18 2025-11-17
Q2 2025 $-8.88 2025-08-14
Q1 2026 $-0.05 2026-05-15
FY 2025 $-30.92 2026-03-27

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

AIM vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
62.59 / 5.21 med
+1101% premium
Net margin vs peers
-15861.4% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.